It’s only fair to share… Pariceract CAS 1919820-28-2 MFC20H30N4O2 MW358.5 g/mol 5,7-dimethyl-N-[trans-4-(pentyloxy)cyclohexyl]pyrazolo[1,5-a]pyrimidine-3-carboxamidebeta-glucocerebrosidase activator, antiparkinsonian, BIA 28-6156, LTI-291, LIT291, LTI-00291, BIA28-6156, LTI- 91, LIT 291, LTI 00291, Gcase activator 1, V9WUN9UUU8 Pariceract (INNTooltip International Nonproprietary Name; developmental code name BIA 28-6156 or LTI-291) is a β-glucocerebrosidase (GCase) activator or positive allosteric modulator which is under development for the treatment of Parkinson’s disease.[1][2][3][4][5] It is taken orally.[1] GCase is a lysosomal enzyme encoded by the gene GBA1.[4][5] Loss-of-function mutations in …